Platelet and Plasma Market

• In April 2020, in the wake of COVID-19 pandemic, OneBlood, a not-for-profit blood center, initiated the collection of platelet and plasma from recovered patients of coronavirus. The collected plasma is transfused into the COVID-19 affected patients that aids them in recovery. The company’s active participation will serve for its growth in the industry

• November 2022: Crown Aesthetics rebranded its product ProGen PRP Advantage to ProGen PRP Eclipse. This simple-to-use system claimed to produce consistent results to fit all of their customers' needs.

In this report, the Platelet and Plasma Market has been segmented by Component, Application, Distribution Channel, and Geography.

Platelet and Plasma Market, Segmentation by Component

The Platelet and Plasma Market has been segmented by Component into Platelets and Plasma.

Platelets

Platelets are critical for patients undergoing treatment for thrombocytopenia, hemorrhage, and bone marrow disorders. With increasing cases of cancer and chemotherapy-related platelet depletion, demand for platelet transfusion is consistently rising. Advancements in platelet storage technologies and extended shelf life solutions are further strengthening market prospects. Donation drives and improved access to mobile apheresis units also contribute to segment growth.

Plasma

Plasma is widely used for managing coagulation factor deficiencies, burns, and liver diseases due to its rich content of proteins and clotting factors. Rising utilization in surgical procedures and critical care units supports sustained market expansion. The increasing awareness of plasma therapies and government initiatives for plasma collection centers are boosting overall plasma availability. Continuous innovation in plasma fractionation is expected to enhance treatment capabilities.

Platelet and Plasma Market, Segmentation by Application

The Platelet and Plasma Market has been segmented by Application into Hemophilia, Thrombocytopenia, Perioperative Indications, Platelet Function Disorders, Coagulation Factor Deficiencies, Thrombotic Thrombocytopenic Purpura, Hemorrhage, Liver Disease, and Others.

Hemophilia

Hemophilia treatment involves plasma-derived clotting factors, making it a prominent application area. With increased early diagnosis and awareness, more patients are gaining access to advanced therapies. Governments and nonprofits are supporting access programs in underserved regions. This segment is expected to witness stable growth with ongoing innovations in plasma and recombinant factor production.

Thrombocytopenia

Thrombocytopenia, characterized by a dangerously low platelet count, often requires immediate platelet transfusions. The condition is prevalent among oncology, transplant, and ICU patients. Increasing adoption of apheresis techniques and the need for ready platelet inventory in hospitals are strengthening the segment. Clinical trials evaluating novel approaches to platelet preservation are also underway.

Perioperative Indications

Platelet and plasma products are frequently used in perioperative care to prevent excessive blood loss and coagulopathy. With the global rise in surgical volumes, especially cardiac and orthopedic surgeries, demand continues to grow. Hospitals are implementing rapid-response transfusion protocols, supporting steady utilization. Improvements in patient blood management programs also drive segment awareness.

Platelet Function Disorders

This segment addresses inherited and acquired disorders such as Glanzmann thrombasthenia and drug-induced platelet dysfunction. Timely intervention with platelet transfusions and supportive therapies is critical. Awareness among hematologists and the expansion of specialized diagnostic labs have strengthened detection rates. As clinical management protocols evolve, demand for targeted platelet products will continue to rise.

Coagulation Factor Deficiencies

Patients with coagulation disorders often require plasma rich in clotting proteins to restore hemostatic balance. Widespread use of fresh frozen plasma (FFP) in trauma, surgery, and congenital deficiencies supports this segment. Growing access to plasma banking in emerging markets and increasing trauma centers are bolstering demand. The push toward pathogen-reduced plasma is also impacting market dynamics.

Thrombotic Thrombocytopenic Purpura

TTP is a rare but life-threatening condition treated through plasma exchange and therapeutic plasma infusions. With increasing awareness of plasma exchange therapy in hematology, treatment coverage is expanding. Advances in disease monitoring and centralization of rare disease care contribute to segment growth. Collaborations among hospitals and blood centers are also improving treatment access.

Hemorrhage

Hemorrhage management across trauma, postpartum bleeding, and surgical events relies heavily on both plasma and platelets. Timely transfusion reduces morbidity, and emergency care settings are becoming more reliant on universal donor plasma. Development of rapid-response transfusion systems and improved supply chains are ensuring timely product availability. This high-demand segment remains integral to transfusion protocols worldwide.

Liver Disease

Patients with liver disease often suffer from coagulopathy, making plasma transfusion necessary to correct clotting deficiencies. Increasing prevalence of chronic liver conditions and cirrhosis is pushing demand. Plasma is frequently used before invasive procedures or during hepatic failure. Hospital networks and transplant centers continue to standardize plasma support protocols, driving sustained market demand.

Others

This includes conditions such as burns, disseminated intravascular coagulation (DIC), and rare hematologic disorders. In these complex cases, personalized plasma and platelet support is often required. As hospitals advance toward precision medicine, the need for specialized transfusion regimens is rising. Continued research and evolving clinical guidelines will broaden the scope of this segment.

Platelet and Plasma Market, Segmentation by Distribution Channel

The Platelet and Plasma Market has been segmented by Distribution Channel into Hospitals, Ambulatory Surgical Centers, and Others.

Hospitals

Hospitals are the largest users of platelet and plasma products, particularly in ICUs, trauma units, and surgical departments. Their in-house blood banks ensure immediate product access. Rising surgical procedures, intensive care admissions, and organ transplants are fueling segment growth. Hospitals also invest in patient blood management systems, enhancing transfusion efficiency and safety.

Ambulatory Surgical Centers

ASCs are increasingly adopting platelet and plasma therapies for outpatient surgical procedures. Their ability to handle minor surgeries and emergency cases requires reliable transfusion partnerships. This segment benefits from quicker turnaround, cost-effectiveness, and growing insurance coverage. Investments in point-of-care diagnostics are further aiding ASC integration into the transfusion ecosystem.

Others

This segment includes standalone blood banks, specialty clinics, and home transfusion programs. With growing demand for remote care and chronic disease management, these distribution points are expanding. Blood banks play a critical role in storage and supply chain logistics. Government-supported mobile transfusion services are also becoming prominent in remote areas, enhancing access.

Platelet and Plasma Market, Segmentation by Geography

In this report, the Platelet and Plasma Market has been segmented by Geography into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Platelet and Plasma Market Share (%), by Geographical Region

North America

North America dominated the market with a share of 43.5%, driven by advanced healthcare infrastructure, strong donation systems, and high demand for transfusions. The U.S. leads in plasma-derived therapy innovations and emergency transfusion protocols. Continuous R&D and federal support for rare disease management further enhance regional dominance.

Europe

Europe held a market share of 26.9%, supported by nationalized healthcare systems and centralized blood services. Countries like Germany and the U.K. prioritize safe and efficient transfusion pathways. The region’s investment in plasma fractionation and clinical standardization boosts demand. Cross-border plasma programs also help maintain product availability.

Asia Pacific

Asia Pacific accounted for 18.2% of the market and is growing rapidly due to rising disease awareness and expanding healthcare capacity. Countries such as China and India are investing heavily in blood and plasma infrastructure. Increasing surgical volumes and trauma cases contribute significantly to market momentum. Donation drives and voluntary apheresis adoption are rising.

Middle East & Africa

This region captured 6.1% of the market and is evolving with investments in modernizing blood banks and hospital systems. Urban hospitals are incorporating transfusion support systems for surgical and emergency care. Government initiatives and NGO support for rare disease transfusion access are also aiding market development in this region.

Latin America

Latin America contributed approximately 5.3%, led by countries like Brazil, Mexico, and Argentina. Growing public-private partnerships and improvement in transfusion safety standards are key drivers. Healthcare reforms and the expansion of critical care services are increasing platelet and plasma use across hospitals and emergency departments.

This report provides an in depth analysis of various factors that impact the dynamics of Global Platelet and Plasma Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Rising Prevalence of Chronic Diseases
• Advancements in Medical Technology

• Increasing Surgical Procedures and Trauma Cases: The increasing number of surgical procedures worldwide, including complex surgeries, has led to a significant rise in the demand for platelets and plasma. These blood components are essential for managing blood loss during surgery, ensuring that patients have a stable supply of necessary blood elements to support recovery and healing. Complex surgeries often involve extensive bleeding, and the use of platelets and plasma is critical in preventing excessive blood loss and promoting clotting.

  Emergency trauma care is another area where the need for platelets and plasma is paramount. Accidents and trauma cases frequently result in severe bleeding, requiring immediate and substantial transfusions of these blood components to stabilize patients. The ability to quickly administer platelets and plasma can be lifesaving, making their availability crucial in emergency medical settings. The rise in global trauma cases underscores the importance of maintaining a robust supply of these vital blood products.

  Elective surgeries are also contributing to the growing demand for platelets and plasma. As healthcare systems advance and more people gain access to surgical procedures for various health conditions, the requirement for these blood components increases. Elective surgeries, while planned, still carry risks of significant blood loss, necessitating the use of platelets and plasma to ensure patient safety and positive surgical outcomes. This trend highlights the ongoing need for efficient blood collection and storage systems to support the expanding surgical demands globally.

Resatraints:

• Regulatory Challenges and Compliance
• High Costs of Collection and Processing

• Risk of Contamination and Disease Transmission: Despite significant advancements in screening and processing technologies, the risk of contamination and transmission of infectious diseases through blood products remains a concern. The complex nature of blood collection and processing necessitates rigorous safety protocols to minimize these risks. Ensuring the safety and purity of platelet and plasma products involves multiple layers of testing and quality control measures, which are essential for protecting patients and maintaining the integrity of healthcare systems.

  Any lapses in these safety measures can have serious repercussions. Even a single incident of contamination or disease transmission can significantly undermine public trust in blood products and the institutions that manage them. This erosion of trust can lead to a decrease in blood donations and a reluctance among healthcare providers to use blood products, which can negatively impact patient care and treatment outcomes.

  Therefore, maintaining high safety standards and continuously improving screening and processing technologies are critical priorities for the platelet and plasma market. Efforts to enhance donor screening, pathogen reduction, and product testing are ongoing and essential to addressing these challenges. By prioritizing safety and building public confidence, the industry can ensure the continued availability and reliability of these vital medical resources.

Opportunities:

• Expansion in Emerging Markets
• Development of Novel Therapies and Applications

• Strategic Partnerships and Collaborations: Collaborations between blood banks, healthcare institutions, research organizations, and pharmaceutical companies are pivotal in driving innovation and enhancing the supply chain in the platelet and plasma market. By working together, these entities can leverage their combined expertise and resources to address complex challenges, such as ensuring the safety and efficacy of blood products, improving collection and processing techniques, and enhancing overall patient care.

  Strategic partnerships aimed at enhancing blood donation programs can significantly boost the availability of platelets and plasma. Joint initiatives can promote awareness and education about the importance of blood donation, increase donor recruitment and retention, and streamline the donation process. These efforts are crucial in maintaining a stable and sufficient supply of blood products, particularly in regions where access to safe blood is limited.

  Collaborations focused on developing advanced products and technologies can drive market growth and enhance the presence of key players in the market. Innovations such as pathogen reduction technologies, improved storage solutions, and novel applications for platelet and plasma products can be accelerated through collaborative research and development efforts. By pooling resources and expertise, stakeholders can bring new and improved products to market more efficiently, meeting the evolving needs of healthcare providers and patients.

Key players in Global Platelet and Plasma Market include;

• Americas Blood Centers
• American Red Cross
• American Association of Blood Banks
• Blood Centers of America
• European Blood Alliance
• Indian Red Cross
• Italian Red Cross
• Japanese Red Cross
• South African Red Cross Society
• OneBlood

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis